Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report

Figure 2 Treatment history and timeline of the patient’s best objective response. A: Treatment history and timeline; B: Illustration of epidermal growth factor receptor L833F mutation in cis with L861Q mutation. BAC: Bevacizumab + pemetrexed + carboplatin; ARMS PCR: Amplification refractory mutation system polymerase chain reaction; NGS: Next generation sequencing; PFS: Progression-free survival; OS: Overall survival; EGFR: Epidermal growth factor receptor; SD: Stable disease; PD: Progressive disease.